Global HIV Therapy Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global HIV Therapy Market Research Report 2024
HIV Therapy involves taking a combination of HIV medicines . HIV Therapy is recommended for everyone who has HIV. HIV Therapy cannot cure HIV, but HIV medicines help people with HIV live longer, healthier lives.
According to Mr Accuracy reports new survey, global HIV Therapy market is projected to reach US$ 3952.5 million in 2029, increasing from US$ 3040 million in 2022, with the CAGR of 3.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole HIV Therapy market research.
Key manufacturers engaged in the HIV Therapy industry include ViiV Healthcare, Gilead Sciences, Inc., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc. and Genentech, Inc., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of HIV Therapy were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole HIV Therapy market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global HIV Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
![](http//localhost/mraccuracy/images/Market%20Recearch%20Graph.jpg)
ViiV Healthcare
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Merck Sharp & Dohme Corp.
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Boehringer Ingelheim International GmbH
AbbVie Inc.
Genentech, Inc.
Mylan N.V.
Segment by Type
Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The HIV Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source![](http://localhost/mraccuracy/images/About Report.webp)
According to Mr Accuracy reports new survey, global HIV Therapy market is projected to reach US$ 3952.5 million in 2029, increasing from US$ 3040 million in 2022, with the CAGR of 3.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole HIV Therapy market research.
Key manufacturers engaged in the HIV Therapy industry include ViiV Healthcare, Gilead Sciences, Inc., GlaxoSmithKline Plc, Merck Sharp & Dohme Corp., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc. and Genentech, Inc., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of HIV Therapy were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole HIV Therapy market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global HIV Therapy market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
![](http//localhost/mraccuracy/images/Market%20Recearch%20Graph.jpg)
By Company
ViiV Healthcare
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Merck Sharp & Dohme Corp.
Bristol-Myers Squibb Company
Janssen Pharmaceuticals, Inc.
Boehringer Ingelheim International GmbH
AbbVie Inc.
Genentech, Inc.
Mylan N.V.
Segment by Type
Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Combination HIV Medicines
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The HIV Therapy report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
![](http://localhost/mraccuracy/images/About Report.webp)